<DOC>
	<DOCNO>NCT00227630</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , pemetrexed disodium cisplatin , work different way stop growth tumor cell , either kill cell stop dividing . Pemetrexed disodium may also stop growth tumor cell block enzymes need cell growth . Radiation therapy use high-energy x-ray kill tumor cell . Giving combination chemotherapy surgery may shrink tumor remove . Giving radiation therapy surgery may kill tumor cell remain surgery . PURPOSE : This phase II trial study well give pemetrexed disodium cisplatin follow surgery radiation therapy work treat patient malignant pleural mesothelioma .</brief_summary>
	<brief_title>Pemetrexed Disodium Cisplatin Followed By Surgery Radiation Therapy Treating Patients With Malignant Pleural Mesothelioma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine feasibility neoadjuvant chemotherapy comprise pemetrexed disodium cisplatin follow extrapleural pneumonectomy high-dose postoperative 3D-conformal radiotherapy , term 90-day progression-free survival , patient malignant pleural mesothelioma . Secondary - Determine toxicity regimen patient . - Determine progression-free survival overall survival patient treat regimen . OUTLINE : This non-randomized , multicenter study . - Neoadjuvant chemotherapy : Patients receive pemetrexed disodium IV 10 minute cisplatin IV 2 hour day 1 . Treatment repeat every 3 week 3 course absence disease progression unacceptable toxicity . Patients evaluate 3 week completion neoadjuvant chemotherapy . Patients without disease progression proceed surgery . - Extrapleural pneumonectomy : Within 21-56 day completion neoadjuvant chemotherapy , patient undergo extrapleural pneumonectomy . Patients evaluate 30 day surgery . Patients without disease progression undergo high-dose 3D-conformal radiotherapy . - High-dose 3D-conformal radiotherapy : Beginning 30-84 day surgery , patient undergo high-dose 3D-conformal radiotherapy daily 30 day . After completion study treatment , patient follow day 42 90 , every 3 month 1 year , every 6 month thereafter . PROJECTED ACCRUAL : A total 52 patient accrue study .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant pleural mesothelioma All subtypes allow T13 , N01 , M0 disease No N2 N3 involvement confirm mediastinoscopy within 21 day study entry No clinical invasion mediastinal structure ( e.g. , heart , aorta , spine , esophagus ) No widespread chest wall invasion except focal chest wall lesions No clinical radiological evidence shrink hemithorax No clinically significant thirdspace fluid ( e.g. , pleural effusion ascites ) manage thoracentesis pleurodesis PATIENT CHARACTERISTICS : Age Under 70 Performance status WHO 01 Life expectancy Not specify Hematopoietic WBC &gt; 3,500/mm^3 Absolute neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Hemoglobin ≥ 11 g/dL Hepatic AST ALT &lt; 1.5 time upper limit normal ( ULN ) Bilirubin &lt; 1.5 time ULN Alkaline phosphatase &lt; 1.5 time ULN Renal Creatinine clearance ≥ 60 mL/min Acceptable ( predict ) postradiotherapy renal function semiquantitative isotope renography , relative contribution contralateral kidney ≥ 40 % Pulmonary See Disease Characteristics Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment Deemed fit enough undergo study treatment No preexist sensory neurotoxicity &gt; grade 1 No uncontrolled infection No prior concurrent melanoma , breast cancer , hypernephroma No malignancy within past 5 year except carcinoma situ cervix adequately treat basal cell skin cancer No psychological , familial , sociological , geographical condition would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy No concurrent routine use colonystimulating factor neoadjuvant chemotherapy Concurrent secondary prophylactic use allow neoadjuvant chemotherapy No concurrent secondary prophylactic use colonystimulating factor postoperative radiotherapy Chemotherapy No prior chemotherapy mesothelioma Endocrine therapy No concurrent hormonal cancer therapy Radiotherapy No prior radiotherapy low neck , thorax , upper abdomen Surgery See Disease Characteristics Other No concurrent anticancer therapy No concurrent experimental medication No nonsteroidal antiinflammatory drug salicylates 2 day , , 2 day administration neoadjuvant chemotherapy ( 5 day 2 day drug long halflife [ e.g. , naproxen , piroxicam , diflunisal , nabumetone ] )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>epithelial mesothelioma</keyword>
	<keyword>sarcomatous mesothelioma</keyword>
	<keyword>localize malignant mesothelioma</keyword>
	<keyword>recurrent malignant mesothelioma</keyword>
</DOC>